ArticleActa paediatrica (Oslo, Norway : 1992)2025
Oral Doxycycline Was a Safe and Feasible Treatment in Young Children With Neuroborreliosis.
Article in Acta paediatrica (Oslo, Norway : 1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring Cerebrovascular Manifestations of Neuroborreliosis: A Scoping Review.Annals of Indian Academy of Neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimThere is limited evidence on the use of oral doxycycline in young children. We evaluated the feasibility and effectiveness of doxycycline in children under 9 years with neuroborreliosis.
methodsThis retrospective study included all children under 9 years of age treated for neuroborreliosis in the Capital Region of Denmark from 2019 to 2023. Patients were identified through Borrelia burgdorferi antibody tests and International Classification of Disease, 10th revision codes. Outcomes were change of treatment route, intolerable adverse effects of oral doxycycline, progression of symptoms after treatment cessation, continuous symptoms of neuroborreliosis exceeding 6 months, and relapse of neuroborreliosis.
resultsOf 116 children, 63 (54%) received doxycycline initially, 4 (6%) of whom switched to intravenous treatment due to adverse effects or symptom worsening during treatment. Of 46 (40%) receiving intravenous antibiotics followed by doxycycline, 45 (98%) completed the remaining treatment on doxycycline. Seven (6%) patients received intravenous antibiotics only. Of 109 patients receiving doxycycline, two (2%) experienced photosensitivity rash. Symptoms lasting over 6 months were observed in two patients. No patients had symptom progression or relapse during the follow-up period (median 41 months, range 12-66).
conclusionOral doxycycline was effective and feasible in children under 9 years with neuroborreliosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.